FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research
The FDA Shake-Up Continues, And Could Impact Genetic Medicines Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.
Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It Cathie Wood is bullish on biotech companies using gene sequencing, AI, and CRISPR tech to cure previously untreatable diseases.
The Best Stocks to Invest $1,000 in Right Now Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to bear more fruit.
5 Monster Stocks to Hold for the Next 10 Years These companies are just starting to realize the potential in up-and-coming fields, like AI and gene editing.
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise CRSPR Therapeutics has ambitious goals for its gene editing technology and may be getting ready to generate the revenue needed to deliver for shareholders
Can Buying CRISPR Therapeutics and Holding It Forever Make You a Millionaire? The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline.
3 Monster Stocks to Hold for the Next 10 Years The planets are lining up for these three stocks' underlying companies.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought In a rising market, the iconic growth investor is adding to positions trading well below their earlier highs.
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025.
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.
Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program.
